Nat. Rev. Neurol. doi: /nrneurol

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 2 Multiscale modelling in oncology

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Figure 5 Schematic illustration of different clinical trial designs

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 2 Grey matter atrophy in FTD

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Figure 2 Algorithm for immunosuppressive treatment

Figure 2 Precision medicine based on a network approach

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Figure 4 Generation of tau seeds and spread of tau pathology

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Stroke-related deaths and DALYs by country development status

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Clinical aspects of LGMD subtypes

Figure 1 The VEGF family of growth factors

Figure 1 Tau PET images in patients with Alzheimer disease

Figure 2 Cellular pathways implicated in CIPN

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

Figure 2 Sources of data to characterize the ADPKD clinical phenotype

Figure 2 Pathophysiological mechanisms in LGMD

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Determination of the primary site

Figure 2 Network connections of the hypothalamus

Presentation transcript:

Nat. Rev. Neurol. doi:10.1038/nrneurol.2016.196 Figure 3 Biaxial clinical and pathophysiological classification of PD needed for precision medicine Figure 3 | Biaxial clinical and pathophysiological classification of PD needed for precision medicine. Semiological abnormalities (axis I: clinical characteristics) are influenced by identifiable contributions from selected pathologies, and genetic and molecular abnormalities (axis II: genetic–molecular and pathology). This classification system, inspired by the recently proposed reclassification of dystonia67, assumes that a number of recognizable PD phenotypes arise from the combination of specific clinical and pathophysiological abnormalities, which would guide the choice of subtype-specific disease-modifying treatments. TDP-43, TAR DNA-binding protein 43. Espay, A. J. et al. (2017) Precision medicine for disease modification in Parkinson disease Nat. Rev. Neurol. doi:10.1038/nrneurol.2016.196